Teva addresses ‘internal inefficiencies’ with restructuring

28-11-2017

Israel-headquartered Teva has announced a series of organisational and leadership changes as it seeks to address external pressures and internal inefficiencies.


Teva, restructuring, generics, speciality medicine, inefficiencies, research and development

LSIPR